Full Press Release Details
ROCKVILLE, Md., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will present an overview of the Company at the following investor conferences in September 2013:
| Rodman & Renshaw: |
| Presentation Date: Monday, September 9 |
| Time: 11:40am ET |
| Place: Millennium Broadway Hotel, NY |
| Stifel Nicolaus Weisel: |
| Presentation Date: Thursday, September 12 |
| Time: 1:30pm ET |
| Place: Four Seasons Hotel, Boston, MA |
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has one marketed product for epilepsy, Oxtellar XR (extended-release oxcarbazepine), and one approved product for epilepsy, Trokendi XR (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.